N/A N=5 Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System
Stroke · Hemiplegia
Primary: Distance Walked in 6 Minutes — 211; 211; 260; 214 m
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Conservative Treatment of Patients With Temporomandibular Disorders
Temporomandibular Disorders
Primary: Patient-Rated TMD Pain, an 11 Point Numerical Rating Scale (NRS) — 0.9; 1.4; 1.6; 0.7 units on a scale
Phase 3 N=743 An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication — 89.4; 86.2 percentage of responders
Phase 2 N=254 Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
Primary Insomnia
Primary: LS Mean Sleep Efficiency (SE) During Periods 1 and 2 — 75.8; 81.0; 83.4; 86.6 percent of time in bed — p=<0.001
Phase 2 N=74 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
Glioblastoma · Gliosarcoma
Primary: Overall Survival (OS) — 19.8 months
N/A N=92 Developing a Practice-Based Learning and Improvement Quality Improvement (QI) Systems Impact Assessment Questionnaire
Quality Improvement
Primary: Beliefs About Ability to Implement a CQI Project — .80; .28 units on a scale — p=0.02
Phase 3 N=449 Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough Forced Expiratory Volume at 1 Second (FEV1) — 1.499; 1.436 Liters
N/A N=10 Protection of Rectum From High Radiation Doses
Prostate Cancer
Primary: Spacer Volume Half Life — 47 days
Phase 4 N=137 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
HIV Coinfection
Primary: Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48 — 1.4; 1.5 Percentage of participants — p=0.4598
Phase 4 N=538 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines
Meningitis · Meningococcal Disease
Primary: Safety Overview Within 30 Days in Participants Vaccinated With Menactra® — 0; 2 Participants
N/A N=227 Does the Aid of MelaFind Affect Clinical Management Decisions
Melanoma
Primary: Sensitivity — 69.5; 78.0; 71.8 percent of true positives
Phase 3 N=69 A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)
Allergic Rhinitis
Primary: Number of Participants Experiencing at Least One Adverse Event (AE) — 6; 2 participants
Phase 2 N=129 Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months — 2.56 percentage of participants — p=<0.0001
N/A N=80 Optimized Intensity Modulated Irradiation for Head and Neck Cancer
Head and Neck Cancer
Primary: Percentage of Participants With Grade 0-1 Observer-rated Dysphagia — 94 percentage of participants
Phase 2 N=16 Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
Sinusitis · Cystic Fibrosis
Primary: Computed Tomography Evidence of Less Sinus Disease — 5.875; 3 units on a scale — p=0.2